Listen on the go
CORRECT!
Next question
touchNEUROLOGY touchNEUROLOGY
Neuromuscular Diseases
Read Time: 8 mins

Patient-reported Outcomes—An Emerging Cornerstone of Effective Intravenous Immunoglobulin Therapy

Copy Link
Published Online: Mar 23rd 2015 US Neurology, 2015;11(1):40–6 DOI: http://doi.org/10.17925/USN.2015.11.01.40
Authors: Nicholas Silvestri, Shafeeq Ladha, Tahseen Mozaffar, Gretchen Ayer, Lisa M Betts
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Intravenous immunoglobulin (IVIG) therapy is increasingly important in the management of various immune-mediated neuromuscular disorders including chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), myasthenia gravis (MG), and other neuromuscular disorders. Administrative burden, quality of life (QoL) concerns, adverse event prevention, economic pressures, and logistical factors are driving greater IVIG use into the home setting where it is administered by nurses. Patient-reported outcome measures (PROMs) are selfassessment instruments designed to measure a patient’s disability, QoL, or their perceptions of health status in relation to specific diseases. PROMs may be a valuable means of monitoring disease status and treatment efficacy in patients receiving IVIG at home. Case reports and small clinical studies show that various specific and general purpose PROMs, such as the 15-item MG-specific QOL (MG-QOL15) and the Myasthenia Gravis Activities of Daily Living scale (MG-ADL), can provide valuable information for patient monitoring at home. PROMs may help to alert physicians that earlier follow-up or treatment regimen changes are needed. PROM data recording systems such as Walgreens’ PartnerPoint Clinical ManagementSM maintain regular reporting to the physician and enable efficacy and adverse events to be tracked. Pilot studies of patients with neuromuscular disease receiving IVIG at home demonstrate a strong correlation in PROM scores between assessments administered by pharmacy clinical staff and those administered by physicians indicating the reliability and suitability of PROMs for remote patient management. Further work to validate additional commonly used PROMS for autoimmune disease is needed if they are to be useful when administered outside the physician clinic.

Keywords

Patient-reported outcome measures, IVIG therapy, neuromuscular disease, improving care continuum

Article:

Patient-reported Outcome Measures
The primary aim of treating disease is to give patients freedom from symptoms, disability and side effects, and the freedom to function. Objectively and reliably measuring disability and quality of life (QoL) can be challenging but using patient-reported outcome measures (PROMs), in addition to clinical examination by physician, has proved a valuable means of capturing patient status and response to treatment.1–3

In disease management, PROMS can be used to estimate symptoms (severity/tolerability of dysfunction or symptom), function, and health-related QoL [HRQoL], such as psychologic well-being, social, and physical functioning). The US Food and Drug Administration (FDA) encourages validated PROMs as parameters that can support labeling requirements. They can be used as endpoints in clinical studies and in regular clinical use.4 The FDA industry guidelines support the use of outcomes measures for specific neuromuscular disorders such as use of the Rasch-built Overall Disability Scale (R-ODS) in the management of chronic inflammatory demyelinating polyneuropathy (CIDP).5

Case Example 1
A 70-year-old male with a 25-year history of MMN showed right ulnar neuropathy at onset and subsequently showed left foot drop, right radial, and upper trunk symptoms with episodes occurring every 6–8 months at which time a course of 1 g/kg IVIG was prescribed. Following IVIG, he reported a dramatic improvement in addition to better scores on MMT. He regained ability to perform exercises including lifting weights, his hands returned to near normal function, and he reported that the greatest improvement was in his balance. Approximately 4 months after each treatment he started to weaken again and so was treated, as needed, every 6 months. The patient was asked to assess his condition at intervals before and after treatment using the form shown in Figure 1; his resultant scores are shown in Figure 2.

PROMS are also valuable for investigation of the natural history of neuromuscular disease. An example is the 15-item MG-specific QoL scale (MG-QoL15) that was developed from a larger set of 60 items and reduced to a core set.6 In a Japanese study that included 640 consecutive patients with MG, MG-QOL15 scores correlated with prednisolone dose and diseaseseverity.7 MG-QOL15 scores for patients receiving ≤5 mg/day prednisolone were the same as those receiving no prednisolone whereas scores were significantly worse for those receiving >5 mg/day prednisolone.

Another example of a PROM that has provided insights into disease natural history is the Inclusion Body Myositis Functional Rating Scale (IBM-FRS), a 10-point disease-specific functional rating scale designed for use in patients with inclusion body myositis (IBM).8 This test takes 15 minutes to perform, shows good correlation with other test measures, such as manual muscle testing (MMT), and accurately indicates disease status. The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) is another validated PROM that has been used in multiple clinical studies as well as routinely in the clinic and is used more frequency than IBM-FRS.9–12 The ALSFRS consists of four domains: gross motor tasks, fine motor tasks, bulbar functions, and respiratory function, which are not equally weighted. ALSFRS scores change in a linear fashion as ALS progresses whereas that is not fully established with IBM-FRS in IBM.

PROMS are also prominently included among data gathered in various patient registries, which also provide information on the natural history of neurologic disease.13,14 PROMs form a central component of comparative effectiveness research initiatives across a range of different diseases;15–17 they correlate well with assessments of HRQoL;18 and indicate patient perceptions of illness and disease severity.19,20

PROMs help monitor a patient over time and can be instrumental in learning about an individual’s perspective in the clinic. Assessment scales such as the MG-QOL15 are designed to involve patients and include them as part of the decision-making process. PROMs are designed so patients consider their progress in a structured manner, and are useful in many chronic neuromuscular diseases with manifestations that the patient is aware of such as: MG, CIDP, multifocal motor neuropathy (MMN), myopathies, and painful neuropathy.5,21,22 They can be used to determine the efficacy of treatment, especially where improvements can be observed quickly. PROMs, however, are less applicable to diseases in which manifestations are not so clear to the patient or where improvement is not quickly discernible.23-26 Such diseases may include diabetes, hypertension, inherited neuropathy, and dementia. In addition, conditions that develop slowly in which the effects of disease-modifying therapy have gradual and long-term effects are also less suitable for assessment using PROMs. PROMs are also less useful where there are large gaps between assessments. It is important therefore to consider the timing of treatment and follow-up before using PROMs and before selecting which one to use. Despite these limitations, PROMs are useful for many chronic conditions.14,23,24,27

The PROMs used in Case Example 1 were a valuable and reliable means of monitoring MMN and identifying when a dose of intravenous immunoglobulin (IVIG) is necessary or a change in treatment plan is warranted. If a patient is being treated on an as needed basis, PROMs can alert the nurse or physician when clinical intervention is necessary, and in this way assist in managing symptoms to better control the condition.

A variety of useful PROMs exist for the assessment of neuromuscular disease (see Table 1).28–32 Many of these are designed for specific diseases, such as the Myasthenia Gravis Activities of Daily Living (MG-ADL)31 scale, whereas some are applicable to a variety of diseases such as the Short Form 36-item scale (SF-36).28 Other scales include the R-ODS (uses include CIDP and Guillain Barre Syndrome [GBS], and Neurology Quality of Life [system] [NeuroQoL] short forms). These and other patient self-assessment instruments have been assessed and validated by the National Institutes of Health PROMIS network33,34 and by the National Institute of Neurological Disorders and Stroke Common Data Elements (CDE) and are available from their websites.35

PROMs provide the patient perspective but are subjective—the clinician must decide how much weight to give each symptom/outcome measure versus clinical and laboratory findings. Patient circumstances (mood, environment, perception) may change over time and unrelated factors can affect PROM assessments. In addition, some patients seek attention or exaggerate symptoms, which creates artifacts and confounds results.

Despite these shortcomings, PROMs work well for most patients and add value to overall assessment. It is only necessary to choose one or two of the most appropriate scales. It is important to consider what parameters are required before selecting the scale. PROMs are useful in many clinical settings and prospective studies and are likely to be increasingly used as endpoints in clinical studies in the regular use for assessment and monitoring in the clinic.

Opportunities to Improve the Immunoglobulin Patient Care Continuum
The continuum of care provided to patients receiving IVIG therapy is demonstrated in Case Example 2, which is a woman with CIDP.

The choice of treatment in this case of CIDP is between IVIG and corticosteroids. The decision requires consideration or treatment efficacy, side effects/risks, and the convenience of administration at home. Following the decision to administer IVIG at home, to maintain the patient continuum of care a Walgreens’ pharmacist would perform an initial evaluation and counseling. This is designed to proactively reduce the risk for adverse events by determining a detailed medical history. This is important since IVIG therapy is associated with an increased risk for thromboembolism, renal insufficiency or failure, aseptic meningitis syndrome, anaphylaxis, and hemolytic anemia. Baseline PROM assessments of the patient revealed a continued decline in symptoms and QoL during the previous month, an ability to walk less than 10 feet, and always needing a cane or walker for mobility.

The continuum of care therefore begins with the treatment plan created by the clinician. Walgreens’ clinical staff can then help define the risk for adverse events and establish baseline PROM scores. If serious risks are identified, they are reported to the physician and an alternative management plan is devised.

Walgreens PartnerPoint Clinical ManagementSM—Use in Case Example
The Walgreens IG program is a comprehensive IG management approach that utilizes a clinical management technology, Walgreens PartnerPoint Clinical Management.SM PartnerPoint provides patient-specific clinical data, adverse event monitoring, clinical intervention tracking, and disease-specific outcomes. PartnerPoint provides transparent, consistent communication between the home infusion clinical team and the physician. Graphical reports trending clinical outcomes based on PROMs provide the physician tools that can be used to optimize care. This can assist the physician with managing dosing, pre-medication, adjunctive therapies, and IVIG cycle management, ultimately improving patient outcomes and demonstrating efficacy of treatment.

The value of Walgreens PartnerPoint Clinical ManagementSM can be demonstrated by the above CIDP case example. Round two of the patient’s treatment consists of 1 g/kg over 3 days every 4 weeks. One hour into the infusion the patient experiences headache, mild nausea, and flashing. The nurse halts the infusion for 30 minutes, repeats premedications, and decreases the infusion rate, but the headache persists. The pharmacist notifies the physician and for subsequent administrations the infusion rate is decreased and prehydration ordered.

The details of the adverse event are entered into the Walgreens PartnerPoint Clinical ManagementSM system including type, severity score, management, and outcome. This information is communicated to the physician along with plots showing event incidence over time (see Figure 3). Subsequent infusions are tolerated with no further adverse events. Over 6 months, the patient stabilizes and improves. PROMs revealed marked improvements including Inflammatory Neuropathy Cause and Treatment (INCAT) scores decreasing to 1 in the arms and legs and in R-ODs, ambulation, and impression of health status (see Figure 4).

Walgreens PartnerPoint Clinical ManagementSM has a number of advantages for the physician. These include improving the care continuum for the home IG patient and proactively avoiding or managing adverse events. This management system also ensures that PROMs and QoL measures are obtained monthly and that consolidated graphical reports are supplied to the prescribing physician on a regular basis or as requested. In the management of patients with neurologic disease the system provides the following advantages:

  • Provides seamless integration from the clinic to the home.
  • Supports patient management.
  • Uses validated PROMs to assess response to therapy.
  • Facilities short- and long-term clinical monitoring.
  • Demonstrates short- and long-term treatment efficacy.
  • Extends the physician’s clinical reach.

Validation of Disease-specific Patient Reported Outcomes in the Home Environment
The use of IVIG therapy is increasing at a rate of 8–10 %/year with 25 % of this attributed to neurologic disease treatment.36 Due to reduced costs, improved convenience, and better QoL findings,37,38 an increasing proportion of this treatment is carried out in the home rather than the hospital outpatient setting. To enable this change, it is important that monitoring of efficacy and safety using PROMS is consistent with assessments performed by a clinician. There is a lack of comparative data supporting the validity of home versus clinical assessments, so a small study that included nine patients with CIDP and four with MMN was initiated to investigate consistency (see Figure 5).39 Walgreens PartnerPoint Clinical ManagementSM was used to gather data by IGspecialized pharmacists, who received disease-specific training as well as focused training in the use of the individual PROMs in order to ensure consistent and reliable reporting. This team of pharmacists conducted telephone interviews with patients that were synchronised with physician visits with a mean interval between paired assessments of 2.8 days.

There were strong correlations and similarity in mean values between MD and home evaluations of R-ODS CIDP (Pearson Correlation Coefficient R=0.97) (see Table 2) and strong correlations and similarity of mean values in a combined analysis of both CIDP and MMN (see Figure 5) (24 observations, R=0.89). INCAT scores in leg function for both CIDP and MMN showed no significant difference between mean MD and home evaluations (p=0.34 and p=0.17, respectively) and a high correlation for combined analysis (R=0.86). However, mean INCAT scores for arm function showed significant differences for both CIDP and MMN (p<0.05 for both) with home evaluators reporting approximately 1 point less. An analysis of 0–10 pain scale scores of CIDP patients only showed a high correlation (R=0.85) with strong agreement between mean values (p=0.36) (see Table 2).

Case Example 2
A 45-year-old woman with a history of well-controlled type 2 diabetes (glycated hemoglobin [HbA1c] 6.3 %) and hypertension, received metformin and lisinopril. The patient presented with a 5-month history of slow progressive weakness in both arms and legs. She noticed difficulty in climbing stairs, buttoning shirts, and reported numbness and tingling in her hands and feet. Her mental status and cranial nerves were normal and she had normal hand strength and normal neck flexor and extensor strength. She had Medical Research Council (MRC) grade 4/5 strength in deltoids, biceps, wrist and finger extensors, interossei bilaterally. She also had MRC grade 4/5 strength in iliopsoas, hamstrings, quadriceps, foot and toe dorsiflexors bilaterally. Sensory examination demonstrated joint position sense and vibration in the toes. Deep tendon reflexes were absent throughout and gait was mildly wide-based using a cane. INCAT scores30 were: three in arms and two in legs and the R-ODS score was 18. Nerve conduction studies and electromyography were consistent with acquired demyelination. Spinal fluid analysis demonstrated no white blood cells and an elevated blood protein level of 291 mg/dl. The diagnosis was consistent with CIDP. The patient was treated with IVIG 2 g/kg over 5 days (induction dose). Baseline blood urea nitrogen (BUN) and serum immunoglobulin A (IgA) were normal. Home infusion was ordered and completed successfully.

This study involved a small sample size: further investigations with a larger patient population are warranted to confirm the results. The inconsistency between mean INCAT arm scores could be resolved with improved assessor training for this instrument and further analysis to assess agreement of scores in this PROM is planned. However, the data show that the PROMs R-ODS, INCAT leg, and the 0–10 pain scale give almost identical results when patients with CIDP or MMN are evaluated either by a MD in the office-based setting or by a clinician in the home setting. In addition, there was strong correlation for combined CIDP and MMN measures of INCAT scores and arm and leg assessments (R=0.86, 0.66, and 0.84, respectively). This indicates that Walgreens PartnerPoint Clinical ManagementSM can be used to reliably assess patients with neuromuscular disease receiving IVIG in the home setting. In addition, Walgreens Partnerpoint Clinical ManagementSM supports the growing trend of increased use of IVIG away from the hospital setting.

A Retrospective Analysis of Patient-reported Outcomes for 34 Patients with Stiff Person Syndrome Receiving Home IVIG Infusions
IVIG is used to treat a range of neuromuscular disorders, however, there are limited data supporting home treatment of some of these diseases. An example is stiff person syndrome (SPS) in which PROMs have been shown to be valuable in assessing disease status and treatment efficacy. The PROMS used in this study are not validated measures but they may be valuable within the assessment process. This was demonstrated in a retrospective study of 34 patients with SPS receiving IVIG. PROMs were analysed for 18 patients with more than two evaluations more than 30 days apart (see Figure 6).40 Patients had a mean of 5.9 evaluations and an average of 7.9 months between first and last infusion. Evaluations of arm, trunk and leg stiffness, ADL, heightened sensitivity to stimuli, balance, sleeping, and cramping all showed trends towards improvement that were nonsignificant (p=0.13–0.99). The measures used, however, may not be have been sufficiently sensitive to detect significant response to therapy, or the patient subjective assessment may be have been optimistic.

The improving trends seen on PROMs were confirmed by the patients’ subjective impression of current health status: 94 % of patients reported improvement or stable status since the last infusion (p=0.03). In addition, 46 % of patients’ self-assessments agreed with the PROM score change, 21 % partially agreed (between same-improve, or stable-decline, for example), and 33 % disagreed (improve-decline). An analysis of combined scores in a subset of patients (n=14) showed that a mean initial combined score of >5 predicted a treatment response (p=0.04) (see Figure 6). Currently, there are no PROMs specifically designed for SPS but the results indicate that further work to define and validate PROMs for this disease are warranted and further explore assessments that may identify suitable candidates for IVIG treatment.

Discussion and Conclusions
The case reports and studies discussed indicate that PROMs and proven patient management systems add value to the traditional patient assessment. PROMs are increasingly important components in the management of patients with neurologic disease who are receiving IVIG in the home setting. These assessments are simple to perform, most taking only 4–5 minutes, and can be performed even in the busiest clinics and at home. When using PROMs, however, it is essential to recognize which changes are clinically meaningful. Changes of >1 in the INCAT, for example, are regarded as significant. However, it is also important that PROMs are considered as part of a larger picture that includes standard clinical measures and the physician perspective. Trained nurses who visit patients at home may be able to perform various physical measures in addition to collecting PROM results. PROMs are important but are not replacements for objective clinical examinations by a physician.

Home administration of IVIG for a range of neurologic diseases will continue to grow in the future. This trend increases the importance of PROMs as a means of tracking patients’ progress remotely. Such monitoring necessitates validated outcome measures and confidence in them. This also requires reliable patient management and clinical reporting systems such as those in the Walgreens PartnerPoint IG program. PartnerPointSM provides clinicians with patient-specific therapy outcome reports on a regular basis and following adverse events. Such systems establish a flow of information from the nurse to the pharmacist to the physician, maintaining awareness by all parties involved in the patient care continuum. PROMs have been developed for neuromuscular diseases such as CIDP, MMN, and ALS, but there remains a requirement to develop assessments specific to neurologic diseases, such as SPS, to monitor the most appropriate variables and guide management. Data from larger studies will help validate PROMs as a cornerstone in IVIG administration and help to demonstrate therapeutic efficacy in the home infusion population.

Article Information:
Disclosure

Gretchen Ayer and Lisa M Betts are employees of the Walgreens IG Program. Tahseen Mozaffar, Nicholas Silvestri, and Shafeeq Ladha are all consultants for
Walgreens IG program and have no other disclosures.

Correspondence

Lisa M Betts, Walgreens Infusion Services, 2050 S Finley Rd, Suite 20, Lombard, IL 60148-4837, USA. E: lisa.betts@walgreens.com

Support

This article was supported by Walgreens Infusion Services.

Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.

Acknowledgements

The content of the forum presentation was developed and reviewed by the Walgreens IG Program PartnerPoint Clinical ManagementSM Medical Advisory Board (Lisa Christopher-Stine, Tahseen Mozaffar, Nicholas Silvestri, Yuen T So, Shafeeq Ladha) and Ted Burns. Editorial assistance was provided by James Gilbart of Touch Medical Media, London, UK. This article reports the proceedings of a sponsored satellite symposium and as such has not been subject to the journal’s usual peer-review process.

Received

2015-02-06T00:00:00

References

  1. Marshall S, Haywood K, Fitzpatrick R, Impact of patient-reported outcome measures on routine practice: a structured review, J Eval Clin Pract, 2006;12:559-68.
  2. Meadows KA, Patient-reported outcome measures: an overview, Br J Community Nurs, 2011;16:146–51.
  3. Wyrwich KW, Norquist JM, Lenderking WR, et al., Methods for interpreting change over time in patient-reported outcome measures, Qual Life Res, 2013;22:475–83.
  4. Food and Drug Administration USA, 2009; Guidance for industry patient-reported outcome measures: Use in pedical product development to support labeling claims. Available at: http:// www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf (accessed 1 December 2014).
  5. Draak TH, Vanhoutte EK, van Nes SI, et al., Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness, Neurology, 2014;83:2124–32.
  6. Burns TM, Conaway MR, Cutter GR, et al., Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis, Muscle Nerve, 2008;38:957–63.
  7. Utsugisawa K, Suzuki S, Nagane Y, et al., Health-related quality-of-life and treatment targets in myasthenia gravis, Muscle Nerve, 2014;50:493–500.
  8. Rider LG, Werth VP, Huber AM, et al., Measures for Adult and Juvenile Dermatomyositis, Polymyositis, and Inclusion Body Myositis, Arthritis Care Res (Hoboken), 2011;63 Suppl 11:S118-57.
  9. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group, Arch Neurol, 1996;53:141–7.
  10. Cedarbaum JM, Stambler N, Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials, J Neurol Sci, 1997;152 Suppl 1:S1–9.
  11. Lo Coco D, Marchese S, La Bella V, et al., The amyotrophic lateral sclerosis functional rating scale predicts survival time in amyotrophic lateral sclerosis patients on invasive mechanical ventilation, Chest, 2007;132:64–9.
  12. Cedarbaum JM, Stambler N, Malta E, et al., The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III), J Neurol Sci, 1999;169:13–21.
  13. Malek AM, Stickler DE, Antao VC, et al., The National ALS Registry: A recruitment tool for research, Muscle Nerve, 2014;50:830–4.
  14. Santana MJ, Feeny D, Framework to assess the effects of using patient-reported outcome measures in chronic care management, Qual Life Res, 2014;23:1505–13.
  15. Califf RM, The Patient-Centered Outcomes Research Network: a national infrastructure for comparative effectiveness research, N C Med J, 2014;75:204–10.
  16. Methodology Committee of the Patient-Centered Outcomes Research I, Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective, JAMA, 2012;307:1636–40.
  17. Snyder CF, Jensen RE, Segal JB, et al., Patient-reported outcomes (PROs): putting the patient perspective in patient-centered outcomes research, Med Care, 2013;51:S73–9.
  18. Martinez-Martin P, Rodriguez-Blazquez C, Frades-Payo B, Specific patient-reported outcome measures for Parkinson’s disease: analysis and applications, Expert Rev Pharmacoecon Outcomes Res, 2008;8:401–18.
  19. Reddy P, Martinez-Martin P, Brown RG, et al., Perceptions of symptoms and expectations of advanced therapy for Parkinson’s disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson’s disease (PRO-APD), Health Qual Life Outcomes, 2014;12:11.
  20. Stewart JC, Cramer SC, Patient-reported measures provide unique insights into motor function after stroke, Stroke, 2013;44:1111-6.
  21. Burns TM, Conaway M, Sanders DB, et al., The MG Composite: A valid and reliable outcome measure for myasthenia gravis, Neurology, 2010;74:1434–40.
  22. Cats EA, van der Pol WL, Piepers S, et al., Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy, Neurology, 2010;75:818-25.
  23. Peters M, Crocker H, Dummett S, et al., Change in health status in long-term conditions over a one year period: a cohort survey using patient-reported outcome measures, Health Qual Life Outcomes, 2014;12:123.
  24. Peters M, Crocker H, Jenkinson C, et al., The routine collection of patient-reported outcome measures (PROMs) for long-term conditions in primary care: a cohort survey, BMJ Open, 2014;4:e003968.
  25. Pocoski J, Benjamin K, Michaels LA, et al., An overview of current trends and gaps in patient-reported outcome measures used in haemophilia, Eur J Haematol, 2014; 93(Suppl. 75):1–8.
  26. Stull DE, Leidy NK, Jones PW, et al., Measuring functional performance in patients with COPD: a discussion of patient-reported outcome measures, Curr Med Res Opin, 2007;23:2655-65.
  27. El Miedany Y, El Gaafary M, Youssef SS, et al., Incorporating patient reported outcome measures in clinical practice: development and validation of a questionnaire for inflammatory arthritis, Clin Exp Rheumatol, 2010;28:734-44.
  28. Dallmeijer AJ, Dekker J, Knol DL, et al., Dimensional structure of the SF-36 in neurological patients, J Clin Epidemiol, 2006;59:541-3.
  29. Heatwole C, Bode R, Johnson N, et al., Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure, Muscle Nerve, 2014;49:906-14.
  30. Merkies IS, Schmitz PI, van der Meche FG, et al., Reliability and responsiveness of a graduated tuning fork in immune mediated polyneuropathies. The Inflammatory Neuropathy Cause and Treatment (INCAT) Group, J Neurol Neurosurg Psychiatry, 2000;68:669–71.
  31. Muppidi S, Wolfe GI, Conaway M, et al., MG-ADL: still a relevant outcome measure, Muscle Nerve, 2011;44:727–31.
  32. Salsman JM, Victorson D, Choi SW, et al., Development and validation of the positive affect and well-being scale for the neurology quality of life (Neuro-QOL) measurement system, Qual Life Res, 2013;22:2569–80.
  33. National Institutes of Health (NIH), PROMIS Dynamic tools to measure health outcomes from the patient perspective, 2014. Available at: http://www.nihpromis.org/default#2 (accessed 2 December 2014).
  34. Cella D, Yount S, Rothrock N, et al., The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years, Med Care, 2007;45:S3–S11.
  35. National Institutes of Health (NIH), NINDS Common data elements Neuromuscular diseases, 2014. Available at: http:// www.commondataelements.ninds.nih.gov/NMD. aspx#tab=Data_Standards (accessed 2 December 2014).
  36. Marketing Research Bureau IVIG/SCIG 2017. A Forecast Of The Polyvalent Immune Globulin Market (IVIG/SCIG) Market In The United States From 2012-2017, 2011. Available at: http:// marketingresearchbureau.com/list-of-reports/ivig-scig-forecast/ (accessed 5 January 2015).
  37. Katzberg HD, Rasutis V, Bril V, Home IVIG for CIDP: a focus on patient centred care, Can J Neurol Sci, 2013;40:384–8.
  38. Sewell WA, Brennan VM, Donaghy M, et al., The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies, J Neurol Neurosurg Psychiatry, 1997;63:106–9.
  39. Ayer G, Christopher-Stine L, Ladha S, et al., Validation of Patient Reported Outcomes in the Home Infusion Setting in the Management of Patients With Neuromuscular Disease, American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM), Savannah, GA US, 2014.
  40. Ladha S, Ayer G, Souayah N, A retrospective analysis of patient-reported outcomes for 34 patients with stiff person syndrome receiving home IVIG infusions, Neurology, 2014;82(Supplement):P7.113.
  41. Nelson ND, Trail M, Van JN, et al., Quality of life in patients with amyotrophic lateral sclerosis: perceptions, coping resources, and illness characteristics, J Palliat Med, 2003;6:417–24.
  42. Cortese A, Machado P, Morrow J, et al., Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials, Neuromuscul Disord, 2013;23:404–12.

Further Resources

Share this Article
Related Content In Neuromuscular Diseases
Neuromuscular Diseases
Updates in the Use of Vamorolone and Steroids in the Treatment of Duchenne Muscular Dystrophy
Bridget McGowan, Nancy L Kuntz Read Time: 5 mins

touchREVIEWS in Neurology. 2023;19(2):7-9

Duchenne muscular dystrophy (DMD) is an X-linked recessive, progressive and universally fatal disease in the spectrum of dystrophinopathies,1 with an incidence of 21.4 patients in 100,000 live male births worldwide.2,3 Historically, patients with DMD would lose ambulation by the age of 10 due to muscle weakness and die by the age of 20 from respiratory failure […]

Neuromuscular Diseases
LGMDR1 with Prominent Limb–Joint Contractures and Inflammatory Changes Misdiagnosed as Scleromyositis with a Novel CAPN3 Mutation: A Case Report
Youssef Abida, Hanene Benrhouma, Emna Farhat Read Time: 8 mins

touchREVIEWS in Neurology. 2023;19(1): DOI: https://doi.org/10.17925/USN.2023.19.1.46

Highlights Limb–joint contractures may represent an important clinical clue of muscle dystrophies, as they limit the spectrum of the diagnosis assumptions. Limb–girdle muscular dystrophies phenotype can rarely be a clinical presentation of retractile myopathies, except for non-specific Achilles tendon tightness. Anti-PM/Scl antibody screening using line-blot assays and commercial antibody–panel testing is likely to detect false-positive antibodies. Dysferlinopathies, calpainopathy and facioscapulohumeral muscular dystrophy are the conditions most frequently confused […]

Neuromuscular Diseases
Hirayama Disease: Review on Pathophysiology, Clinical Features, Diagnosis and Treatment
Saranya B Gomathy, Ayush Agarwal, Ajay Garg Read Time: 14 mins

touchREVIEWS in Neurology. 2022;18(2):109–16 DOI: https://doi.org/10.17925/USN.2022.18.2.109

Hirayama disease (HD) is a lower motor neurologic disorder that manifests in young males in their early 20s, manifesting with gradually progressive weakness and wasting of C7-T1 innervated muscles. Dynamic magnetic resonance imaging (MRI) clinches the diagnosis, and treatment is mainly supportive using a cervical brace, and in refractory cases, surgical. This review aims to […]

Trending In Neuromuscular Diseases:

Updates in the Use of Vamorolone and Steroids in the Treatment of Duchenne Muscular Dystrophy
Neuromuscular Diseases
    • Download PDF More Actions
    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32 social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72